Michael Diamond

This study identifies TMEM106B as an alternative receptor for SARS-CoV-2 S-E484D variant entry, independent of ACE2, in airway-derived cell models.

This study shows that MXRA8-dependent infection of PDGFRα+ mesenchymal cells by CHIKV increases vascular permeability, enabling hematogenous spread and joint swelling.

The paper uses human iPSC-derived neurons to study WNV effects, identifying strain-specific neuroattenuation and pathogenic signatures not seen in conventional cell lines.

The paper shows that the gut microbiota of undernourished women negatively affects placental development in mice, with potential bacterial targets for improving prenatal outcomes.

The paper identifies CD164 as an endolysosomal receptor for clade A New World arenaviruses, expanding the receptor switching paradigm observed in Old World arenaviruses.

This study shows that gut microbe-derived short-chain fatty acids reduce joint inflammation after alphavirus infection by modulating immune cell activity.

Booster SARS-CoV-2 mRNA vaccine recruits and broadens GC B cell responses targeting a highly conserved site on receptor binding domain of spike glycoprotein.

This study shows that IL-25 induces memory ILC2s in the small intestine that provide long-term protection against barrier pathogens.

This study shows molnupiravir reduces BRBV infection and disease in mice by lowering virus burden and improving immune and clinical outcomes.

This study identifies amino-acid mutations in CHIKV envelope proteins that affect entry in human and mosquito cells, revealing species-specific determinants of viral tropism.

This study identifies three HS-binding sites on EEEV E2 glycoprotein that contribute to both HS and protein receptor-dependent infection, affecting disease and mosquito infectivity.

This study identifies LDLR-mediated clathrin-dependent endocytosis as the mechanism by which HlyA from UPEC causes renal epithelial toxicity.

The paper shows that short 5' UTRs in viral mRNAs are recognized by the IFIT2-IFIT3 complex, leading to translation inhibition and antiviral activity.

This paper introduces a rapid, portable assay to measure neutralizing antibodies against SARS-CoV-2 variants using gold nanoparticles and optical extinction detection.

This study shows that mucosal adenoviral-vectored vaccines provide durable protection against XBB.1.16 infection in nonhuman primates, outperforming intramuscular boosting in reducing virus replication in both upper and lower airways.

This study shows that boosting mice with mRNA vaccines in the ipsilateral or contralateral arm leads to equivalent immune responses and protection against SARS-CoV-2 Omicron.

This study shows that intestinal helminth infection reduces T cell responses to an mRNA SARS-CoV-2 vaccine and weakens protection against Omicron but not the ancestral strain.

This study shows that Omicron variant-matched boosters after prototype mRNA vaccines induce cross-neutralizing antibodies against SARS-CoV-2 and sarbecoviruses by imprinting prior immune responses.

This study identifies MXRA8 as a promoter of adipose tissue whitening that drives obesity, showing its role in reducing UCP1 expression and protecting against obesity in mice.

This study identifies multiple VLDLR binding sites used by EEEV and develops a decoy receptor to neutralize infection.

The paper compares SARS-CoV-2 antigenicity across assays and in human and animal model sera, finding similar immunodominance patterns and antigenic maps but differences in titer magnitude and assay-specific fold change.

The paper introduces a thermodynamically coupled biosensor to rapidly detect neutralizing antibodies against SARS-CoV-2 strains in serum samples.

The paper designs and characterizes trivalent miniprotein binders that neutralize SARS-CoV-2 variants with low pM IC50 values and provide prophylactic and therapeutic protection in mice.

This paper develops tetravalent SARS-CoV-2 neutralizing antibodies that are more potent and resistant to escape mutations than bivalent versions.

The paper designs picomolar SARS-CoV-2 miniprotein inhibitors using computational methods and experimental validation, showing high potency and structural similarity to computational models.